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Abstract
Androgen-independent prostate cancer usually develops as a relapse following androgen ablation 
therapy. Removing androgen systemically causes vascular degeneration and nutrient depletion of 
the prostate tumor tissue. The fact that the malignancy later evolves to androgen-independence 
suggests that some cancer cells are able to survive the challenge of energy/nutrient deprivation. 
AMP-activated protein kinase (AMPK) is an important manager of energy stress. The present 
study was designed to investigate the role of AMPK in contributing to the survival of the 
androgen-independent phenotype. Most of the experiments were carried out in the androgen-
dependent LNCaP cells and the androgen-independent C4-2 cells. These two cell lines have the 
same genetic background, since the C4-2 line is derived from the LNCaP line. Glucose 
deprivation (GD) was instituted to model energy stress encountered by these cells. The key 
findings are as follows. First, the activation of AMPK by GD was much stronger in C4-2 cells 
than in LNCaP cells, and the robustness of AMPK activation was correlated favorably with cell 
viability. Second, the response of AMPK was specific to energy deficiency rather than to amino 
acid deficiency. The activation of AMPK by GD was functional, as demonstrated by appropriate 
phosphorylation changes of mTOR and mTOR downstream substrates. Third, blocking AMPK 
activation by chemical inhibitor or dominant negative AMPK led to increased apoptotic cell death. 
The observation that similar results were found in other androgen-independent prostate cancer cell 
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lines, including CW22Rv1 abd VCaP, provided further assurance that AMPK is a facilitator on the 
road to androgen-independence of prostate cancer cells.
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1. Introduction
Solid tumors are often characterized by a disorganized vasculature, which tends to hinder 
the delivery of oxygen and nutrients to the cancer cells [1,2]. In order to adapt to this hostile 
microenvironment, cancer cells need to develop a mechanism so that they may continue to 
thrive despite the challenge of hypoxia and nutrient deficiency. AMP-activated protein 
kinase (AMPK) is an important energy sensor whose main function is to block ATP-
consuming processes and stimulate ATP-producing processes by phosphorylating rate-
limiting enzymes associated with metabolic pathways and modifying signal transduction 
cascades [3,4]. In times of hypoxia or glucose deprivation, AMPK is activated to conserve 
or restore cellular ATP for survival [5,6]. Some examples of AMPK-mediated effects 
include suppression of mammalian target of rapamycin (mTOR) signaling to reduce protein 
synthesis, and promotion of fatty acid oxidation and glycosis [7,8].
Immunohistochemical analysis of hypoxia markers [9] and molecular imaging [10] lend 
support to the conclusion that prostate tumors, like many solid tumors in other organ sites, 
are afflicted by poor blood flow and unstable oxygenation. Consistent with these findings is 
the observation that AMPK is highly expressed in about 40% of human prostate cancer 
specimens [11], suggesting that a sizable proportion of them is under metabolic stress. 
However, the role of AMPK is controversial in prostate cancer cell studies in vitro in which 
cells are cultured in a normal condition, i.e. in the absence of either hypoxia or nutrient 
depletion. In one study, the down-regulation of AMPK by either small interfering RNA or 
chemical inhibitor was shown to decrease cell growth [11]. In contrast, other studies 
reported that a similar decrease in growth was achieved by activating AMPK with 
pharmacological agents [8]. As a whole, these in vitro studies are difficult to interpret 
because the effect of AMPK might have been distorted or masked by other factors which are 
more dominant than AMPK when cells are exposed to normoxia and when there is no lack 
of nutrients.
Androgen ablation therapy is commonly employed in the treatment of advanced prostate 
cancer. Signs of vascular degeneration, hypoxia, and metabolic stress in the prostate tumor 
tissue are exacerbated following surgical or medical castration [12]. After a short remission 
period, the majority of prostate cancer begins to progress and becomes androgen-
independent. Clearly a subset of cells is able to survive the low oxygen and nutrient 
environment and emerge with a different phenotype. The present study was designed to 
investigate the role of AMPK in contributing to the development of androgen-independent 
prostate cancer. Glucose deprivation was instituted to model the metabolic stress 
encountered by these cells so that the significance of AMPK can be put into the proper 
context. Most of the experiments were carried out in both the androgen-dependent LNCaP 
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cells and the androgen-independent C4-2 cells. These two cell lines have the same genetic 
background, since the C4-2 line is derived from the LNCaP line [13]. In order to address the 
issue of lineage specificity, additional experiments were also conducted in two other 
androgen-independent cell models: CW22Rv1 and VCaP [14].
2. Materials and methods
2.1. Cell cultures
LNCaP, CW22Rv1 and VCaP prostate cancer cell lines were obtained from the American 
Type Culture Collection, Manassas, VA. C4-2 cells were provided by Dr. Leland Chung 
(Department of Urology, Emory University School of Medicine, Atlanta, GA). All cells, 
except VCaP, were cultured in RPMI 1640 medium. VCaP cells were cultured in DMEM as 
recommended by ATCC. Both types of media were supplemented with 10% fetal bovine 
serum, 2 mmol/L of glutamine, 100 units/mL of penicillin, and 100 μg/mL of streptomycin. 
The cultures were maintained at 37°C in an atmosphere of 5% CO2 and 95% air. Cells with 
<10 passage number were used in all experiments.
2.2. Glucose or amino acid deprivation
In all except one experiment, the cultures were subjected to glucose deprivation. This was 
achieved by replacing the regular RPMI 1640 medium with a glucose-free RPMI 1640 
medium from Invitrogen (Carlsbad, CA). For the amino acid deprivation experiment, cells 
pre-cultured in complete regular medium were subjected to the L-glutamine and L-leucine 
free RPMI medium (MP Biochemicals) for the required duration of the experiment.
2.3. Cell survival and cell death analysis
Analysis of cell survival after glucose deprivation (GD) was performed by using the MTT 
assay as described in our previous publication [15]. The data are expressed as percent 
surviving cells after GD. Untreated cells served as the control in every experiment. Total 
cell death (both necrotic and apoptotic cell death) determination was done by flow 
cytometric analysis. Cells were stained with propidium iodide (PI, 5μg/ml) according to the 
method described in previous publications [16,17]. This method offers the advantage of 
providing quantitative data. The fluorescence of PI was captured with a 585 nm filter in a 
FACScan flow cytometer (Becton Dickinson). Both dot plot and histogram analyses were 
performed using the FCS Express Software in a population of 20,000 cells. Total cell death 
was calculated as the percent of PI-positive nuclear staining cells. The results in the 
treatment group are expressed as fold of change compared to the control. In the experiments 
with transfected siRNA, the cells were harvested with trypsin solution at 24 and 48 h after 
GD. Cell counts were performed in triplicates with a hemocytometer using trypan blue 
(0.2%) exclusion to identify viable cells. Non-viable (positively-stained) cells were 
calculated as a percent of total.
2.4 LDH Release as a Marker of Necrosis
Cell necrosis was estimated by determining lactate dehydrogenase (LDH) release in the 
medium [18] in which cells were cultured with or without glucose for 48 h. The activity of 
LDH was measured by the CytoTox 96 Cytotoxicity Assay Kit (Promega, Madison, WI) 
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according to manufacturer’s protocol. The quantitation of LDH in the treatment group is 
expressed as fold of change compared to the control.
2.5. Chemical inhibition of AMPK activation
Compound C, obtained from Calbiochem, was used to inhibit AMPK activation at a 
concentration of 10 μM. DMSO was added as the vehicle for the untreated control.
2.6. Dominant negative AMPK expression
A dominant negative form of AMPK (DN-AMPKα1) was generated originally by David 
Carling and co-workers as described previously [19]. The DN-AMPKα coding regions were 
sub-cloned into pcDNA-Neo to generate pcDNA-Neo-DN-AMPKα1. The construct was 
obtained as a gift from Dr. Jill Suttles (University of Louisville School of Medicine, 
Louisville, KY). The mycDN-AMPKα1, which encodes N-terminal Myc-tag with DN-
AMPKα1 cloned in pCDNA3, was obtained from Dr. David Carling’s laboratory 
(Hammersmith Hospital, London, UK). Prostate cancer cells were transiently transfected 
with Lipofectamine 2000 according to the manufacturer’s instructions.
2.7. AMPKα1 Knockdown by siRNA
All materials for siRNA transfection were purchased from Ambion (Austin, TX). Transient 
transfection of siRNA was done using a protocol recommended by the manufacturer. The 
AMPKα1 siRNA sequences, which were accessed from the Ambion pre-designed siRNA 
library (ID number s100), were as follows: sense: 5′-GGAUCCAUCAUAUAGUUCAtt-3′, 
antisense: 5′-UGAACUAUAUGAUGGAUCCtc-3′. Non-silencing siRNA sequence was 
used as the negative control. All siRNAs, obtained in lyophilized and annealed form, were 
resuspended in diethylpyrocarbonate-treated distilled water to achieve a stock concentration 
of 20 μM, and stored at −20°C in 50-μl aliquots. C4-2 cells were plated onto 6-well plates to 
achieve 60% confluency. Lipofectamine 2000 transfection reagent (Invitrogen) and fresh 
medium containing 40 nM of either negative control or AMPKα1 siRNA were incubated in 
separate tubes for 5 min. The transfection reagent and siRNA solution were then combined 
and incubated for 25 min at room temperature to allow complex formation. The siRNA-
transfection reagent complexes were added drop-wise to each well of cells bathed in 2 ml of 
fresh medium. Transfected cells were cultured in a glucose deprived condition for 48 h, and 
harvested for survival and Western blot analysis.
2.8. Western blot analysis
Equal amounts of protein were analyzed in duplicate by SDS-PAGE. Protein concentrations 
were measured by the BCA protein assay kit as per manufacturer’s protocol (Pierce). 
Antibodies to AMPKα, phospho-AMPKα (Thr172), mTOR, phospho-mTOR (Thr2446 and 
Ser2448), p70S6K, phospho-p70S6K (Ser371), S6, phospho-S6 (Ser235/236), Myc-tag and 
PARP were purchased from Cell Signaling Technology (Beverly, MA). Anti–β-actin was 
obtained from Sigma and anti-GAPDH from Santa Cruz Biotechnology. Immunoreactive 
proteins were detected with a HRP-conjugated secondary antibody (Biorad) and visualized 
by using an enhanced chemiluminescence detection system (Amersham Bioscience).
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The Student t-test was used to determine statistical difference between treatment and control 
values. A P value of <0.05 is considered significant.
3. Results
3.1. Enhanced survival and AMPK activation in C4-2 cells following glucose deprivation 
(GD)
LNCaP (androgen-dependent) and C4-2 (androgen-independent) prostate cancer cells were 
subjected to GD for 5 consecutive days. No cell growth was observed during this period. 
The effect of GD on cell survival, as determined by the MTT assay, is shown in Fig. 1A. 
Cells remained mostly viable after 1 day of GD. By day 5, about 60% of LNCaP cells did 
not survive, as opposed to only 25% of C4-2 cells, suggesting that C4-2 cells are more 
resistant to GD-induced cell death.
Since GD is known to cause phosphorylated AMPK activation, the protein level of phospho-
AMPKα was determined by Western blotting at 8, 16 and 24 h after GD (Fig. 1B). These 
early time points were chosen in order to detect the changes that occurred before the onset of 
cell death. The results showed that phospho-AMPKα increased at a much faster rate and 
reached a higher level in C4-2 cells than in LNCaP cells. The total amount of AMPKα was 
unchanged in either cell type.
For comparison with GD, the effect of amino acid deprivation (AAD) on cell growth was 
examined in a second experiment (Fig. 1C). Both LNCaP and C4-2 cells were able to grow 
in the presence of AAD, although at a slower pace than the control culture in complete 
medium. However, AAD caused a similar percentage of growth inhibition in both cell types. 
Thus the survival advantage of C4-2 cells over LNCaP cells with GD is not reproduced with 
AAD. There were only minor changes in phospho-AMPKα level in either cell type 
following AAD (Fig. 1D). The above data suggest that AMPK activation responds 
specifically to energy deficiency rather than to amino acid or nutrient deficiency. GD 
removes a major source of energy for maintaining cellular functions, whereas cells can 
breakdown non-essential proteins to recycle amino acids during AAD.
3.2. Functional analysis of AMPK activation following glucose deprivation (GD)
Two direct phosphorylation targets of AMPK, acetyl CoA carboxylase (ACC) and 
mammalian target of rapamycin (mTOR), were examined following GD. The same time 
course was set up for this experiment as for the AMPK activation experiment. ACC is a key 
enzyme in the pathway of fatty acid biosynthesis and is inactivated by phosphorylation. 
Inhibiting ACC activity is an energy saving measure. The increase of phospho-ACC was 
more rapid and robust in C4-2 cells than in LNCaP cells (Fig. 2A). Thus the rate and 
magnitude of ACC phosphorylation paralleled closely the pattern of AMPK activation in 
each cell type. AMPK modifies mTOR phosphorylation at two different sites. It promotes 
phosphorylation at Thr2446 and inhibits phosphorylation at Ser2448 [20,21]. In LNCaP 
cells, phosphorylation at Thr2446 increased 1.8 fold at 24 h, but phosphorylation at Ser2448 
remained fairly stable (Fig. 2A). In C4-2 cells, phosphorylation increased at Thr2446 and 
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decreased at Ser2448 at a much faster pace. The trend is in line with the steeper rise of 
AMPK activation in this cell model.
mTOR plays an important role in any cell stress situation [22]. The phosphorylation changes 
of mTOR caused by AMPK result in a lower activity of mTOR. Next, the activity of mTOR 
was assessed by determining the phosphorylation status of two target substrates: S6 and 
p70S6K (Fig. 2B). Following GD, the decrease of both phospho-S6 and phospho-p70S6K 
occurred earlier in C4-2 cells than in LNCaP cells, suggesting that the down-regulation of 
mTOR activity was functional.
3.3. Inhibiting AMPK activation decreases survivability of C4-2 cells following glucose 
deprivation (GD)
In order to address the significance of AMPK activation to cell survival in an energy-
stressed environment, an experiment was performed to study survival response when AMPK 
activation was blocked. Compound C is a small molecule inhibitor of AMPK activation 
[11]. Phospho-AMPKα changes in LNCaP and C4-2 cells at 72 h following GD and in the 
absence or presence of Compound C are shown in Fig. 3A. In LNCaP cells, the increase of 
phospho-AMPKα, which was detectable at earlier time points, was no longer evident at 72 h 
after GD. Compound C had minimal effect on baseline level of AMPK activation in LNCaP 
cells. In contrast, C4-2 cells still maintained a higher level of phospho-AMPKα at 72 h after 
GD. In the presence of Compound C, phospho-AMPKα was reduced to near baseline level. 
More importantly, 75% of C4-2 cells did not survive the GD condition compared to 40% of 
LNCaP cells when Compound C was present in the culture (Fig. 3B). The data therefore 
suggest that AMPK activation is critical to the resistance of C4-2 cells against energy 
deprivation.
3.4. Dominant negative AMPK (DN-AMPKα) expression augments cell death of glucose-
deprived C4-2 cells
The expression of a DN-AMPKα1 construct in C4-2 cells resulted in a marked down-
regulation of phospho-AMPKα at both 24 and 48 h (Fig. 4A). Total AMPKα increased 
slightly in the transfected cells because the AMPKα antibody also recognizes the DN-
AMPKα. As expected, the loss of AMPKα activation due to the DN-AMPKα led to a 
decrease of phospho-ACC and phospho-mTOR (Thr2446), and an increase of phospho-
mTOR (Ser2448). The ACC and mTOR data, which are shown in Fig. 4A, confirmed that 
the DN-AMPKα construct was exerting its intended biochemical effects downstream.
In terms of survival response to GD, the expression of the DN-AMPKα caused more cells to 
die, as determined by nuclear propidium iodide staining of dead cells (Fig. 4B). With the 
loss of AMPK activation, there was a 4-fold and 2.3-fold increase of total cell death at 24 h 
and 48 h, respectively. It was not possible to do the cell death experiment past the 48 h time 
point because of the transient expression of the DN-AMPKα.
In order to confirm the successful transfection of the DN-AMPKα, we used the myc-tagged 
AMPKα plasmid and tracked the expression of myc by Western blot analysis (Fig. 4C). The 
results show that myc was detected only in the mycDN-AMPKα transfected cells. Similar to 
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the data shown in Fig. 4A, total AMPKα protein was increased in the transfected cells, but 
there was a decrease of phospho-AMPKα.
3.5. siRNA mediated AMPKα knockdown enhances cell death of glucose-deprived C4-2 
cells
In addition to the use of DN-AMPKα, we also carried out another experiment with siRNA 
knockdown of AMPKα expression in C4-2 cells undergoing glucose deprivation. The data 
in Fig. 5A show that total AMPKα was decreased in the siRNA-transfected cells, and so 
were phospho-AMPKα, phospho-ACC and phospho-mTOR (Thr2446). As expected, the 
opposite effect was observed with phospho-mTOR (Ser2448). The trypan blue exclusion 
assay demonstrated that cell death due to GD was significantly increased when AMPK 
activation was jeopardized by RNA interference (Fig. 5B). These observations clearly 
indicate that AMPK activation is important for survival of the C4-2 cells under GD.
3.6. Resistance of other androgen-independent prostate cancer cells to glucose 
deprivation-induced cell death and the reversal of this effect by DN-AMPKα
Two other human androgen-independent prostate cancer cell lines, CW22Rv1 and VCaP, 
were studied with respect to their sensitivity to GD. Compared to LNCaP cells, both 
CW22Rv1 and VCaP cells showed greater survivability in the absence of glucose (Fig. 6A). 
Only 25% of LNCaP cells survived GD, as opposed to 45% of CW22Rv1 cells and 85% of 
VCaP cells. Consistent with the finding in C4-2 cells, the expression of the DN-AMPKα in 
CW22Rv1 and VCaP cells also caused more cell death (Fig. 6B). The increase was 1.6-fold 
in CW22Rv1 cells and 3-fold in VCaP cells. Both CW22Rv1 and VCaP cells showed robust 
and persistent increases of AMPK activation following GD (Fig. 6C). The knockdown of 
phospho-AMPKα by the DN-AMPKα, as confirmed by Western blotting, also correlated 
well with increased cell death in both models.
3.7. AMPK inhibition causes enhanced apoptotic cell death in a glucose-deprived 
condition
Glucose deprivation may lead to two types of cell death, necrosis or apoptosis [23,24]. Cell 
death detection by propidium iodide staining does not distinguish between these two types. 
An experiment was carried out to determine whether GD caused necrosis and whether 
AMPK inhibition by the DN-AMPKα produced more necrotic or apoptotic cell death. The 
LDH release assay was used to assess the extent of necrosis, and the results are expressed as 
fold of change compared to the value obtained in control cultures without GD (Fig. 7A). 
There was a 6-fold increase in C4-2 cells, an 8-fold increase in CW22Rv1 cells, and a 2-fold 
increase in VCaP cells after 48 h of GD. It should be noted that the amount of LDH release 
due to necrosis is cell specific, and that the magnitude of the increase of LDH release cannot 
be equated directly to the magnitude of cell death induction. Expression of the DN-AMPKα 
in these cells did not lead to a further increase of LDH release even though total cell death 
was increased as seen in an earlier experiment (Fig. 6B). The inference is that inhibiting 
AMPK activation causes cells to die by apoptosis.
To test the above hypothesis, PARP cleavage, which is a hallmark of apoptotic cell death 
[25], was used to assess the extent of apoptosis under various treatment conditions. C4-2 and 
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CW22Rv1 cells were subjected to GD with or without DN-AMPKα expression. There was 
little PARP cleavage at 18 h after GD, but the cleaved PARP was definitely evident at 36 h 
in both cell lines (Fig. 7B). Inhibiting AMPK activation by the DN-AMPKα resulted in a 
1.7-fold increase of PARP cleavage in C4-2 cells, and a 1.8-fold increase in CW22Rv1 cells. 
The results suggest that the major mode of cell death induction by down-regulating AMPK 
activation is accounted for by apoptosis.
4. Discussion
A major conclusion of the present study is that AMPK activation offers a survival advantage 
to androgen-independent prostate cancer cells in an energy-starved microenvironment. The 
conclusion is underlined by two key findings. First, the activation of AMPK by glucose 
deprivation is much stronger in androgen-independent than in androgen-dependent prostate 
cancer cells, and the robustness of AMPK activation is correlated favorably with cell 
viability. Second, blocking AMPK activation by chemical inhibitor or dominant negative 
AMPK leads to increased cell death. Androgen-independent prostate cancer, which is very 
resistant to chemotherapy, usually develops as a relapse following androgen ablation 
therapy. Since androgen is critically involved in maintaining vascular integrity of prostate 
tumor tissue [12] and regulating the expression of nutrient transporters in prostate cancer 
cells [26], removing androgen systemically by medical or surgical castration would be 
expected to lead to nutrient depletion and consequently, to regression of the malignancy. 
The fact that the malignancy later evolves to androgen-independence implies that not all the 
cancer cells are eradicated by androgen ablation. Some cells are able to survive the insult of 
energy/nutrient depletion and continue to propagate. The present findings suggest that 
AMPK may help cells overcome the challenge of energy deprivation.
The LNCaP and C4-2 cell lines used in this study are appropriate models to reconstruct the 
molecular events associated with the transition from androgen-dependence to androgen-
independence. The C4-2 cell line is derived from a recurrent LNCaP xenograft after 
castration of the host animal [13]. C4-2 cells have therefore undergone a selection process 
and have acquired the ability to withstand a nutrient starvation crisis. The observation of a 
greater AMPK activation in C4-2 cells than in the parental LNCaP cells is supportive of the 
role of AMPK in contributing to the development of a more aggressive pathology. The fact 
that similar results were found in other androgen-independent prostate cancer cell lines, 
including CW22Rv1 and VCaP, provides further assurance that AMPK is a facilitator on the 
road to androgen-independence. It is apparent that these cells, after gaining androgen-
independence, still retain certain signature phenotype which has given them the resilience to 
rebound from episodes of energy deprivation.
AMPK is a crucial manager of energy stress [5]. One main function of AMPK is to inhibit 
mTOR activity so that protein synthesis is limited to a minimum [27,28]. AMPK activation 
by low glucose and oxygen has been shown to suppress mTOR activity even in the presence 
of full growth factors and active Akt and Erk signaling [21,28,29]. This is an energy 
conservation measure. When faced with an energy crisis, cells need to put survival as a 
priority before expending energy for proliferation. The pro-survival effect of down-
regulating mTOR in stress situations has been reported previously [30]. AMPK is also 
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known to stimulate autophagy [31]. In times of energy stress, autophagy may be considered 
as a way to recycle nutrients in order to support essential cellular functions [31,32]. AMPK 
activation may also mediate the recruitment of glucose transporters to the cell membrane 
[3,33]. This effect is particularly relevant to prostate cancer cells following androgen 
ablation because of diminished nutrient delivery as a result of vascular disintegration. 
Additionally, AMPK contributes to the Warburg effect of anaerobic metabolism 
(necessitated by hypoxic condition in the tumor) by favoring glycosis over the Krebs cycle 
in generating ATP [3].
In summary, AMPK allows prostate cancer cells to remain viable when they suddenly lose 
the fountain of sustenance fueled by the androgen signal. Cells which are successful in 
achieving a vibrant AMPK activation phenotype would be better equipped for transition to 
androgen-independence. AMPK is thus a legitimate target of intervention to block the 
development of androgen-independent prostate cancer. The induction of apoptotic, rather 
than necrotic, cell death by abrogating AMPK activation, as demonstrated in the present 
study, is advantageous clinically. Tumor necrosis often provokes inflammation and cytokine 
response that may encourage growth of the surviving cancer cells [24]. Denying prostate 
cancer cells the ability to adapt to metabolic stress and increasing the rate of cell killing at 
the time of androgen ablation therapy would be a worthwhile strategy to pursue in 
controlling androgen-independent prostate cancer.
5. Conclusion
The present study provides evidence to support the conclusion that AMP-activated protein 
kinase (AMPK) offers a survival advantage to prostate cancer cells in an energy-starved 
condition that is often experienced following androgen ablation therapy. Cells which are 
successful in achieving a vibrant AMPK activation phenotype are better equipped for 
transition to androgen-independence. AMPK is thus a legitimate target of intervention to 
block the development of androgen-independent prostate cancer.
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ACC acetyl coenzyme A carboxylase
AAD amino acid deprivation
AMPK AMP-activated protein kinase
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DN dominant negative
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Effect of glucose or amino acid deprivation on cell survival and AMPK activation in LNCaP 
and C4-2 cells. (A) MTT cell survival data following glucose deprivation. The results (mean 
± SD, n=3) are expressed as % surviving cells compared to the value of the untreated 
control, which is set as 100%. *significantly different from each other, P<0.05. (B) Western 
blot of phosphorylated or total AMPK in cells following glucose deprivation (GD). (C) 
MTT cell growth data following amino acid deprivation (AAD). (D) Western blot of 
phosphorylated or total AMPK following AAD.
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Effect of glucose deprivation (GD) on phospho-ACC, phospho-mTOR, phospho-S6 and 
phospho-p70S6K. The substrates in (A) are the direct targets of AMPK, while the substrates 
in (B) are the direct targets of mTOR.
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Effect of Compound C on AMPK activation (A) and cell survival (B) in LNCaP and C4-2 
cells subjected to glucose deprivation. The cell survival data were obtained at day 3. The 
results from Compound C-treated cells are expressed as a percentage of the value from 
DMSO (vehicle) treated cells (set as 100%). *significantly different from each other, 
P<0.05.
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Effect of dominant negative AMPK (DN-AMPKα) on AMPK activity (A) and cell death (B) 
in C4-2 cells following glucose deprivation (GD). (A) Western blot of phospho-AMPK, 
phospho-ACC, and phospho-mTOR. (B) Cell death data as determined by flow cytometric 
analysis of propidium iodide-stained cells. Effect of AMPK knockdown on cell death is 
expressed as fold of increase compared to the value observed in the absence of knockdown. 
*significantly different than the GD only value, P<0.05. (C) Western blot of phospho-
AMPK, total AMPK and myc of mycDN-AMPKα transfected cells.
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Effect of AMPK-siRNA on AMPK activity (A) and cell death (B) in C4-2 cells following 
glucose deprivation (GD). (A) Western blot of phospho-AMPK, phospho-ACC, and 
phospho-mTOR. (B) Cell death data as determined by trypan blue exclusion analysis. Effect 
of AMPK knockdown on cell death is expressed as percent of trypan blue positive cells. 
*significantly different than the GD only value, P<0.05.
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Effect of glucose deprivation (GD) on cell survival and cell death in CW22Rv1 and VCaP 
cells with or without AMPK activation knockdown by DN-AMPKα. (A) MTT cell survival 
data after 5 days of GD. The results are expressed as % surviving cells compared to the 
value of the untreated control, which is set as 100%. *significantly different than the LNCaP 
value, P<0.05. (B) Cell death data as determined by flow cytometric analysis of propidium 
iodide-stained cells. The effect of AMPK activation knockdown on cell death is expressed 
as fold of increase compared to the value observed in the absence of knockdown. 
*significantly different than the GD only value, P<0.05. (C) Confirmation of decreases of 
phospho-AMPKα by DN-AMPKα.
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Effect of AMPK knockdown by DN-AMPKα on cell death induction following glucose 
deprivation (GD). (A) LDH release as an indicator of necrotic cell death. The data are 
expressed as fold of increase compared to the value from untreated control cells (set as 1). 
(B) PARP cleavage as an indicator of apoptotic cell death. The Western blot shows both full 
length and cleaved PARP with or without DN-AMPKα transfection.
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